{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+II+Infection", "query": { "condition": "Human Immunodeficiency Virus II Infection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 143, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+II+Infection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T17:13:12.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002235", "title": "A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 6, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 5, "location_summary": "Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Hampton", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002235" }, { "nct_id": "NCT02140255", "title": "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Nevirapine (NVP)", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "VRC01", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 1120, "start_date": "2015-01-23", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140255" }, { "nct_id": "NCT00106678", "title": "Typology of Adherence in Adolescents: Phase II", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infection" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "12 Years to 24 Years" }, "enrollment_count": 1200, "start_date": "2004-06", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 16, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106678" }, { "nct_id": "NCT00029913", "title": "A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "HIV Vaccine Trials Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 54, "start_date": "2002-04", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2010-09-02", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00029913" }, { "nct_id": "NCT00000842", "title": "A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Peripheral Nervous System Disease" ], "interventions": [ { "name": "Nerve Growth Factor, Recombinant Human", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 270, "start_date": null, "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 14, "location_summary": "Los Angeles, California • San Mateo, California • Stanford, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000842" }, { "nct_id": "NCT00131560", "title": "Safety and Efficacy of T Cell Genetic Immunotherapy for HIV", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "VRX496-Modified Autologous T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "VIRxSYS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2005-07", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 5, "location_summary": "Palo Alto, California • Norwalk, Connecticut • Miami, Florida + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131560" }, { "nct_id": "NCT00008463", "title": "A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Interferon alfa-2a", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 132, "start_date": "2000-11", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 24, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008463" }, { "nct_id": "NCT00000761", "title": "Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Interferon gamma-1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 20, "start_date": null, "completion_date": "1997-10", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000761" }, { "nct_id": "NCT00000820", "title": "A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": null, "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000820" }, { "nct_id": "NCT02038881", "title": "Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "IMVAMUNE®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 87, "start_date": "2014-04-28", "completion_date": "2017-05-10", "has_results": true, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-09-26T17:13:12.184Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038881" } ] }